Septerna (NASDAQ:SEPN) Shares Gap Down – Time to Sell?

Septerna, Inc. (NASDAQ:SEPN)’s share price gapped down prior to trading on Monday . The stock had previously closed at $23.69, but opened at $22.88. Septerna shares last traded at $23.43, with a volume of 2,627 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SEPN. Cantor Fitzgerald began coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target on the stock. Wells Fargo & Company began coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price on the stock. TD Cowen assumed coverage on shares of Septerna in a research note on Tuesday, November 19th. They set a “buy” rating for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective on the stock.

Septerna Price Performance

The firm has a 50 day moving average of $23.73.

Insider Activity at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of Septerna stock in a transaction on Monday, October 28th. The stock was acquired at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the transaction, the insider now owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.